Cardiff Oncology to Showcase Onvansertib's Potential in Combating Therapy-Resistant HER2-Low Breast Cancer at AACR Annual Meeting 2026

Cardiff Oncology will present preclinical data on its oral PLK1 inhibitor, onvansertib, at the AACR Annual Meeting 2026. The data shows that onvansertib enhances the antitumor activity of trastuzumab deruxtecan (T-DXd) and reverses resistance in therapy-resistant HER2-low breast cancer models. The poster presentation will take place on April 19, 2026. Onvansertib is currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer.